Condition Directory

Breast Cancer clinical trials

Directory of U.S. ClinicalTrials.gov public records for Breast Cancer. Browse Breast Cancer recruiting trials, filter by phase, sponsor, location, or intervention, and open the official ClinicalTrials.gov study record for each result.

By Clinical Trials Finder Guidance last reviewed June 10, 2026 Data synced November 15, 2026 Report an issue

ClinicalTrials.gov public records Last synced Nov 15, 2026, 4:00 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

7089

Shown on this page

Current sort

How Breast Cancer studies are organized in the registry

Breast cancer listings are usually subtype-specific: receptor status appears directly in titles and condition fields, so subtype terms narrow results far better than stage words alone. Many studies also restrict to either early-stage or metastatic settings, which is visible in the title or eligibility section of the official record.

Terms that often appear in related listings

triple-negative HER2-positive hormone receptor-positive metastatic breast cancer

These describe how studies tend to be titled and grouped on ClinicalTrials.gov — they are search vocabulary, not medical guidance.

Showing 757–768 of 7,089 matching trials for Breast Cancer.

Live ClinicalTrials.gov results.

Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Open in full search

Conditions: Neoplasms (Cancer / Tumors), Colorectal Neoplasms, Lung Neoplasms, Endometrial Neoplasms, Breast Neoplasms, Pancreatic Neoplasms, Head and Neck Neoplasms, Kidney Neoplasms, Glioma, Ovarian Neoplasms, Stomach Neoplasms
Interventions: Not listed
Lead sponsor: Harvard Medical School (HMS and HSDM); Other
Eligibility: Not listed
Enrollment: 30,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Breast Cancer, Lung Cancer, Colon Cancer, Solid Tumor, Adult
Interventions: PEPRR, Pep-Pal; Behavioral
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 64 Years
Enrollment: 538 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Ductal Carcinoma in Situ
Interventions: Magtrace; Drug
Lead sponsor: University of Florida; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Early Stage Estrogen Receptor (ER) Positive Breast Cancer
Interventions: Active Surveillance; Other
Lead sponsor: University of Pittsburgh; Other
Eligibility: 70 Years and older · Female only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Cancer
Interventions: TTX-080, pembrolizumab, cetuximab, FOLFIRI; Drug
Lead sponsor: Tizona Therapeutics, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 41
States / cities: Tucson, Arizona • Los Angeles, California • Newport Beach, California + 37 more

Conditions: Breast Cancer
Interventions: pHLIP® ICG NIRF imaging; Diagnostic Test
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 2
States / cities: Montvale, New Jersey • New York, New York

Conditions: Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer
Interventions: Giredestrant, Fulvestrant or an Aromatase Inhibitor (Physician Choice), LHRH Agonist; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 303 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 3
States / cities: Marietta, Georgia • Cleveland, Ohio • Tigard, Oregon

Conditions: Breast Neoplasm
Interventions: ExoPred; Diagnostic Test
Lead sponsor: EXoPERT; Industry
Eligibility: 40 Years and older · Female only
Enrollment: 330 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Honolulu, Hawaii

Conditions: Endometrial Neoplasms, Soft Tissue Sarcoma (STS), Breast Neoplasms
Interventions: AL58805, AL8326, Eribulin, Fulvestrant; Drug
Lead sponsor: Advenchen Pharmaceuticals, LLC.; Industry
Eligibility: 18 Years and older
Enrollment: 138 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Breast Cancer
Interventions: Talazoparib, Avelumab; Drug
Lead sponsor: Georgetown University; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • Salt Lake City, Utah

Conditions: Triple Negative Breast Neoplasms
Interventions: alpelisib, placebo, nab-paclitaxel; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 137 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 5
States / cities: Los Angeles, California • Baton Rouge, Louisiana • Rochester, Minnesota + 2 more

Conditions: Breast Cancer (Locally Advanced or Metastatic), Healthy Volunteers (HV), Unhealthy Volunteers, Breast Cancer Screening
Interventions: Epigenetic Assay; Other
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years and older
Enrollment: 450 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2033
U.S. locations: 1
States / cities: Glen Burnie, Maryland

About this Breast Cancer clinical trials directory page

What this page lists: U.S. ClinicalTrials.gov public records that list Breast Cancer as a study condition, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
How to narrow results: Use the filters above to scope by intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Breast Cancer.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Breast Cancer clinical trials

How Breast Cancer studies are organized in the registry

Filter and sort this condition

Live official records

A Preregistered Multi-Cohort Evaluation of the FATHOM AI System for Molecular Testing Prioritization to Support Clinical Trial Enrollment

Developing a Virtual Stress Management Intervention for Spousal/Partnered Caregivers of Solid Tumor Cancer Patients.

Evaluation of Novel Iron-based Lymphatic Mapping Agent, Magtrace, for Delayed Sentinel Lymph Node Biopsy (SLNB) in Ductal Carcinoma In-Situ (DCIS)

Active Surveillance in Older Women With ER+ Breast Cancer

TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers

A Study of Multiparametric MRI and pHLIP® ICG in Breast Cancer Imaging During Surgery

A Study Evaluating the Efficacy and Safety of Giredestrant Compared With Physician's Choice of Endocrine Monotherapy in Participants With Previously Treated Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (acelERA Breast Cancer)

A Prospective Study to Develop and Clinically Validate an in Vitro Diagnostic Medical Device That Uses Blood to Classify Patients at High Risk for Breast Cancer

A Study of AL58805 in Advanced, Metastatic GYN, STS or Breast Cancers

TALAVE: Induction Talazoparib Followed by Combination of Talazoparib and Avelumab in Advanced Breast Cancer

Study Assessing the Efficacy and Safety of Alpelisib + Nab-paclitaxel in Subjects With Advanced TNBC Who Carry Either a PIK3CA Mutation or Have PTEN Loss

Signature Development and Validation Protocol for an Epigenetic Assay in Diagnosing Breast Cancer

About this Breast Cancer clinical trials directory page